Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Schematic indicating clinical, cell culture, and mouse protocols used in this study.
  • Fig. S2. R. mucosa treatment compared to historical placebo controls.
  • Fig. S3. Changes in serum cytokines associated with R. mucosa treatment.
  • Fig. S4. R. mucosa from healthy volunteers activates epithelial cell migration and proliferation.
  • Fig. S5. TNF may be a mediator of AD.
  • Fig. S6. R. mucosa activity is dependent on NFκB, STAT3, TNFR, and CXCR2.
  • Fig. S7. R. mucosa from individuals with AD shows reduced phospholipid production.
  • Fig. S8. Metabolomics assessment of skin tape strips indicates lipid pathway modulation.
  • Fig. S9. R. mucosa activity was not influenced by serotonin receptor blockade.
  • Fig. S10. R. mucosa from individuals with AD show increased chemotaxis and flagellin transcript production.
  • Fig. S11. Schematic showing proposed mechanisms.
  • Table S1. Demographics and baseline characteristics of patient cohort.
  • Table S2. Clinical characteristics of participants enrolled in the study.
  • Table S3. Clinical improvement after R. mucosa treatment stratified according to EASI severity at enrollment.
  • Table S4. Treatment emergent and adverse events after R. mucosa treatment.
  • Table S5. Primers used for strain-specific identification.
  • References (7280)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). MetaboAnalyst report file for metabolomics assessments.
  • Data file S2 (Microsoft Excel format). Individual-level data for all figures.